Cargando…

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy

The incidence of malignant melanoma is rising worldwide and survival for metastatic disease is still poor. Recently, new treatment options have become available. Still, predictive biomarkers are needed to optimise treatment for this patient group. In this study, we investigated the predictive value...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuster, Cornelia, Akslen, Lars A, Stokowy, Tomasz, Straume, Oddbjørn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317286/ https://www.ncbi.nlm.nih.gov/pubmed/30225999 http://dx.doi.org/10.1002/cjp2.116

Ejemplares similares

Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study
por: Schuster, Cornelia, et al.
Publicado: (2016)

β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma
por: Schuster, Cornelia, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
por: Schuster, Cornelia, et al.
Publicado: (2012)

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
por: Seo, Mikyung Kelly, et al.
Publicado: (2020)

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019)

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2018)

Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma
por: Hugdahl, Emilia, et al.
Publicado: (2019)

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma
por: Ladstein, Rita G, et al.
Publicado: (2010)

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
por: Krüger, Kristi, et al.
Publicado: (2021)

Tumor necrosis is associated with increased alpha(v)beta(3 )integrin expression and poor prognosis in nodular cutaneous melanomas
por: Bachmann, Ingeborg M, et al.
Publicado: (2008)

Lymphatic vessel density and prognosis in cutaneous melanoma
por: Straume, O, et al.
Publicado: (2004)

Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma
por: Straume, O, et al.
Publicado: (2005)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases
por: Dillekås, Hanna, et al.
Publicado: (2014)

Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
por: Dunbar, Erin M., et al.
Publicado: (2012)

The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
por: Mansfield, Aaron S., et al.
Publicado: (2013)

Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up
por: El Matri, Leila, et al.
Publicado: (2021)

Are 90% of deaths from cancer caused by metastases?
por: Dillekås, Hanna, et al.
Publicado: (2019)

Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma
por: Hugdahl, Emilia, et al.
Publicado: (2018)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
por: Bai, Long, et al.
Publicado: (2015)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
por: Liu, Yingmiao, et al.
Publicado: (2013)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2018)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal
por: Demicheli, Romano, et al.
Publicado: (2019)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel
por: Mendiola, Marta, et al.
Publicado: (2016)

p16(INK4A) as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy
por: Geisler, S, et al.
Publicado: (2000)

Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
por: Kanat, Ozkan, et al.
Publicado: (2019)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review
por: Poku, Edith, et al.
Publicado: (2014)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes
por: Håkansson, A, et al.
Publicado: (2001)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_et6s3sgngcmln31rljf60f1n5e